Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

PURPOSE: [(177)Lu]Lu-PSMA-617 radio-ligand therapy (PSMA-RLT) is emerging in patients with an advanced metastatic castration-resistant prostate cancer (mCRPC). Here, we aimed to estimate the results of PSMA-RLT in terms of response, progression-free survival (PFS), and overall survival (OS) in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasul, Sazan, Hacker, Marcus, Kretschmer-Chott, Elisabeth, Leisser, Asha, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh, Wadsak, Wolfgang, Mitterhauser, Markus, Hartenbach, Markus, Haug, Alexander R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005080/
https://www.ncbi.nlm.nih.gov/pubmed/31781834
http://dx.doi.org/10.1007/s00259-019-04584-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005080/
https://www.ncbi.nlm.nih.gov/pubmed/31781834
http://dx.doi.org/10.1007/s00259-019-04584-1

Ejemplares similares